Invesco
RARE icon

Invesco’s Ultragenyx Pharmaceutical RARE Stock Holding History

Invesco’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.07M Buy
289,572
+59,301
+26% +$1.34M ﹤0.01% 2098
2025
Q4 		$5.3M Sell
230,271
-564,578
-71% -$18.6M ﹤0.01% 2224
2025
Q3 		$23.9M Buy
794,849
+70,734
+10% +$2.12M ﹤0.01% 1380
2025
Q2 		$26.3M Sell
724,115
-489,167
-40% -$17.6M ﹤0.01% 1308
2025
Q1 		$43.9M Sell
1,213,282
-486,474
-29% -$20.2M 0.01% 1090
2024
Q4 		$71.5M Buy
1,699,756
+25,487
+2% +$1.26M 0.01% 917
2024
Q3 		$93M Buy
1,674,269
+405,951
+32% +$20.7M 0.02% 817
2024
Q2 		$52.1M Buy
1,268,318
+765,466
+152% +$32.7M 0.01% 994
2024
Q1 		$23.5M Buy
502,852
+72,834
+17% +$3.44M 0.01% 1365
2023
Q4 		$20.6M Buy
430,018
+44,577
+12% +$1.73M ﹤0.01% 1393
2023
Q3 		$13.7M Buy
385,441
+8,092
+2% +$321K ﹤0.01% 1557
2023
Q2 		$17.4M Buy
377,349
+308,730
+450% +$14.3M ﹤0.01% 1440
2023
Q1 		$2.75M Sell
68,619
-2,481
-3% -$106K ﹤0.01% 2509
2022
Q4 		$3.29M Buy
71,100
+8,992
+14% +$354K ﹤0.01% 2437
2022
Q3 		$2.57M Sell
62,108
-1,244
-2% -$63.9K ﹤0.01% 2533
2022
Q2 		$3.78M Buy
63,352
+4,760
+8% +$293K ﹤0.01% 2421
2022
Q1 		$4.25M Sell
58,592
-501,548
-90% -$34.9M ﹤0.01% 2451
2021
Q4 		$47.1M Sell
560,140
-143,224
-20% -$11.7M 0.01% 1071
2021
Q3 		$63.4M Buy
703,364
+249,738
+55% +$22.6M 0.02% 959
2021
Q2 		$43.3M Sell
453,626
-3,676
-0.8% -$383K 0.01% 1139
2021
Q1 		$52.1M Sell
457,302
-124,678
-21% -$17M 0.01% 1046
2020
Q4 		$80.6M Buy
581,980
+318,225
+121% +$37.8M 0.02% 825
2020
Q3 		$21.7M Buy
263,755
+241,833
+1,103% +$20M 0.01% 1258
2020
Q2 		$1.71M Buy
21,922
+7,650
+54% +$506K ﹤0.01% 2544
2020
Q1 		$634K Buy
14,272
+7,594
+114% +$394K ﹤0.01% 2954
2019
Q4 		$285K Sell
6,678
-435
-6% -$17.9K ﹤0.01% 3436
2019
Q3 		$304K Sell
7,113
-276
-4% -$15K ﹤0.01% 3425
2019
Q2 		$469K Sell
7,389
-254
-3% -$16.2K ﹤0.01% 3335
2019
Q1 		$530K Sell
7,643
-4,133
-35% -$236K ﹤0.01% 3287
2018
Q4 		$512K Buy
11,776
+1,474
+14% +$80.6K ﹤0.01% 3263
2018
Q3 		$786K Sell
10,302
-99,124
-91% -$8.06M ﹤0.01% 3244
2018
Q2 		$8.41M Buy
109,426
+100,772
+1,164% +$6.51M ﹤0.01% 1785
2018
Q1 		$441K Sell
8,654
-253,319
-97% -$12.8M ﹤0.01% 3374
2017
Q4 		$12.2M Buy
261,973
+216
+0.1% +$10.6K ﹤0.01% 1471
2017
Q3 		$13.9M Buy
261,757
+173
+0.1% +$10.3K 0.01% 1386
2017
Q2 		$16.2M Buy
261,584
+92,616
+55% +$5.58M 0.01% 1288
2017
Q1 		$11.5M Buy
168,968
+12,045
+8% +$918K ﹤0.01% 1475
2016
Q4 		$11M Sell
156,923
-1
-0% -$71 ﹤0.01% 1475
2016
Q3 		$11.1M Buy
+156,924
New +$10M ﹤0.01% 1430
2015
Q3 		– Sell
-53
Closed -$5K – 3949
2015
Q2 		$5K Buy
+53
New +$4.12K ﹤0.01% 4211

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Invesco's RARE Position: Q1 2026 in Review

Invesco increased its Ultragenyx Pharmaceutical (RARE) stake by 26% in Q1 2026, buying an estimated $1.34M and bringing the position to 289,572 shares worth $6.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2098.

Invesco first reported a position in RARE in Q2 2015 and has held it in 40 quarters since. The position peaked at $93M in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Invesco held 289,572 shares of Ultragenyx Pharmaceutical worth $6.07M as of Q1 2026.
  • Invesco bought 59,301 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.34M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2098 holding.
  • Invesco first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 40 quarters since.
  • Invesco's Ultragenyx Pharmaceutical position peaked at $93M in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.